Plus Therapeutics, Inc.
PSTV
$0.2025
-$0.1061-34.38%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.21M | 5.82M | 5.73M | 5.51M | 6.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.21M | 5.82M | 5.73M | 5.51M | 6.08M |
| Cost of Revenue | 9.57M | 10.58M | 11.19M | 10.82M | 9.47M |
| Gross Profit | -4.37M | -4.76M | -5.46M | -5.31M | -3.39M |
| SG&A Expenses | 10.57M | 9.94M | 9.19M | 8.79M | 8.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.14M | 20.52M | 20.38M | 19.61M | 17.98M |
| Operating Income | -14.93M | -14.70M | -14.65M | -14.11M | -11.90M |
| Income Before Tax | -27.12M | -12.98M | -12.89M | -13.23M | -11.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.12 | -12.98 | -12.89 | -13.23 | -11.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.12M | -12.98M | -12.89M | -13.23M | -11.77M |
| EBIT | -14.93M | -14.70M | -14.65M | -14.11M | -11.90M |
| EBITDA | -14.22M | -13.97M | -13.98M | -13.47M | -11.27M |
| EPS Basic | -2.51 | -2.07 | -2.42 | -3.05 | -3.19 |
| Normalized Basic EPS | -1.57 | -1.29 | -1.51 | -1.91 | -1.99 |
| EPS Diluted | -2.77 | -2.33 | -2.68 | -3.31 | -3.19 |
| Normalized Diluted EPS | -1.46 | -1.18 | -1.40 | -1.80 | -1.99 |
| Average Basic Shares Outstanding | 36.79M | 26.54M | 23.18M | 18.55M | 14.56M |
| Average Diluted Shares Outstanding | 41.03M | 30.79M | 27.42M | 22.79M | 14.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |